OpenLB
Open Library of Bioscience
Advanced Search
Current opinion in pediatrics
Apr 01, 2022;34 (2): 140-146.

Prevention of pneumococcal infections in childhood: two decades of progress.

Emmanuel B Walter, Michael J Smith
Author Information
  1. Emmanuel B Walter: Department of Pediatrics.
  2. Michael J Smith: Department of Pediatrics.
PMID: 35232949 DOI: 10.1097/MOP.0000000000001112

Abstract

PURPOSE OF REVIEW: This review highlights progress in combating pediatric pneumococcal disease in the era of pneumococcal conjugate vaccines (PCVs). This review is timely given the development of increased valency PCVs for potential use in children.
RECENT FINDINGS: Countries implementing vaccination programs with PCVs have witnessed dramatic reductions in cases of childhood invasive pneumococcal disease (IPD). In the US, the largest decline of IPD followed the introduction of 7-valent PCV with additional decreases following the switch to 13-valent PCV (PCV13). Despite these gains, IPD still occurs in the US but at much lower rates. Likewise, pneumonia hospitalizations and office visits for otitis media have decreased. Nasopharyngeal colonization with pneumococci has persisted due to replacement by nonvaccine serotypes: colonizing non-PCV13 serotypes have less invasive potential. The PCV era has also been marked by reductions in the proportions of pneumococcus showing nonsusceptibility or resistance to some antimicrobial agents. Furthermore, PCVs have an excellent safety profile.
SUMMARY: Despite proven safety and efficacy, childhood vaccination programs in some countries do not include PCVs, resulting in the majority of global deaths attributable to pneumococcus. Increased worldwide vaccination of children and the development of higher valency vaccines holds additional promise for further reductions in childhood IPD.

References

  1. Ganaie F, Saad JS, McGee L, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. mBio 2020; 11:e00937-20.
  2. Prevention CfDCa. Epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, DC: Public Health Foundation; 2021.
  3. Lee GM, Kleinman K, Pelton S, et al. Immunization, antibiotic use, and pneumococcal colonization over a 15-year period. Pediatrics 2017; 140:e20170001.
  4. Olarte L, Jackson MA. Streptococcus pneumoniae . Pediatr Rev 2021; 42:349–59.
  5. Butters C, Phuong LK, Cole T, Gwee A. Prevalence of immunodeficiency in children with invasive pneumococcal disease in the pneumococcal vaccine era: a systematic review. JAMA Pediatr 2019; 173:1084–1094.
  6. Organization WH. Pneumococcal Disease 2021. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease . [Accessed date 30th Jan 2022].
  7. Plotkin SA, Orenstein W, Offit PA, Edwards KM. Plotkins's vaccines. 7th edPhiladelphia: Elsevier; 2018.
  8. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187–195.
  9. Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010; 126:e493–505.
  10. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62:521–524.
  11. Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine 2018; 36:6883–6891.
  12. Senders S, Klein NP, Lamberth E, et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States. Pediatr Infect Dis J 2021; 40:944–951.
  13. Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 2012; 31:249–254.
  14. Wyres KL, Lambertsen LM, Croucher NJ, et al. Pneumococcal capsular switching: a historical perspective. J Infect Dis 2013; 207:439–449.
  15. Yildirim I, Little BA, Finkelstein J, et al. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine 2017; 35:4002–4009.
  16. Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent era, 2006–2015. Pediatr Infect Dis J 2016; 35:901–906.
  17. Kaur R, Pham M, Yu KOA, Pichichero ME. Rising pneumococcal antibiotic resistance in the post13-valent pneumococcal conjugate vaccine era in pediatric isolates from a primary care setting. Clin Infect Dis 2021; 72:797–805.
  18. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction – eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 2008; 57:144–148.
  19. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369:1179–1186.
  20. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007; 119:707–715.
  21. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:468–472.
  22. Centers for Disease Control and Prevention. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep 2010; 59:253–257.
  23. Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med 2016; 4:399–406.
  24. Baxter R, Aukes L, Pelton SI, et al. Impact of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease after introduction into routine pediatric use. J Pediatric Infect Dis Soc 2021; 10:141–150.
  25. Gaviria-Agudelo CL, Jordan-Villegas A, Garcia C, McCracken GH Jr. The effect of 13-valent pneumococcal conjugate vaccine on the serotype distribution and antibiotic resistance profiles in children with invasive pneumococcal disease. J Pediatric Infect Dis Soc 2017; 6:253–259.
  26. Kaplan SL, Barson WJ, Lin PL, et al. Invasive pneumococcal disease in children's hospitals: 2014–2017. Pediatrics 2019; 144:e20190567.
  27. Griffin MR, Mitchel E, Moore MR, et al. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines – Tennessee. MMWR Morb Mortal Wkly Rep 2014; 63:995–998.
  28. Ouldali N, Levy C, Minodier P, et al. Long-term association of 13-valent pneumococcal conjugate vaccine implementation with rates of community-acquired pneumonia in children. JAMA Pediatr 2019; 173:362–370.
  29. Lewnard JA, Givon-Lavi N, Dagan R. Effectiveness of pneumococcal conjugate vaccines against community-acquired alveolar pneumonia attributable to vaccine-serotype Streptococcus pneumoniae among children. Clin Infect Dis 2021; 73:e1423–e1433.
  30. Wasserman M, Chapman R, Lapidot R, et al. Twenty-year public health impact of 7- and 13-valent pneumococcal conjugate vaccines in US children. Emerg Infect Dis 2021; 27:1627–1636.
  31. Pilishvili T, Gierke R, Farley MM, et al. , Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 Years of Pneumococcal Conjugate Vaccine (PCV). Open Forum Infect Dis 2020; 7: (Issue Supplement_1): S736–S737.
  32. Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68:1069–1075.
  33. Olarte L, Barson WJ, Bradley JS, et al. Invasive pneumococcal disease in infants aged 0-60 days in the United States in the 13-valent pneumococcal conjugate vaccine era. J Pediatric Infect Dis Soc 2018; 7:249–252.
  34. Andrejko K, Ratnasiri B, Hausdorff WP, et al. Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis. Lancet Microbe 2021; 2:e450–e460.
  35. Hill HA, Yankey D, Elam-Evans LD, et al. Vaccination coverage by age 24 months among children born in 2017 and 2018 – National Immunization Survey-Child, United States, 2018–2020. MMWR Morb Mortal Wkly Rep 2021; 70:1435–1440.
  36. Santoli JM, Lindley MC, DeSilva MB, et al. Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration – United States. MMWR Morb Mortal Wkly Rep 2020; 69:591–593.
  37. Vogt TM, Zhang F, Banks M, et al. Provision of pediatric immunization services during the COVID-19 pandemic: an assessment of capacity among pediatric immunization providers participating in the vaccines for children program – United States, May 2020. MMWR Morb Mortal Wkly Rep 2020; 69:859–863.
  38. Tseng HF, Sy LS, Liu IL, et al. Postlicensure surveillance for prespecified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine 2013; 31:2578–2583.
  39. Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project. Vaccine 2012; 30:2024–2031.
  40. Duffy J, Weintraub E, Hambidge SJ, et al. Febrile seizure risk after vaccination in children 6 to 23 months. Pediatrics 2016; 138:e20160320.
  41. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr 2014; 168:211–219.
  42. Walter EB, Klein NP, Wodi AP, et al. Fever after influenza, diphtheria-tetanus-acellular pertussis, and pneumococcal vaccinations. Pediatrics 2020; 145:e20191909.
  43. Organization WH. Global Market Study Pneumococcal Conjugate (PCV) and Polysaccharide (PPV) Vaccines 2020 [Available from: https://www.who.int/immunization/programmes_systems/procurement/mi4a/platform/module2/Pneumococcal_Vaccine_Market_Study-June2020.pdf . [Accessed date 30th Jan 2022].
  44. Whitney CG, Goldblatt D, O’Brien KL. Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J 2014; 33: (Suppl 2): S172–S181.
  45. Principi N, Esposito S. Pneumococcal disease prevention: are we on the right track? Vaccines 2021; 9:305.

MeSH Term

Child
Humans
Infant
Pneumococcal Infections
Pneumococcal Vaccines
Serogroup
Streptococcus pneumoniae
Vaccines, Conjugate

Chemicals

Pneumococcal Vaccines
Vaccines, Conjugate
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0PCVspneumococcalIPDvaccinationreductionschildhoodPCVreviewprogressdiseaseeravaccinesdevelopmentvalencypotentialchildrenprogramsinvasiveUSadditionalDespitepneumococcussafetyPURPOSEOFREVIEW:highlightscombatingpediatricconjugatetimelygivenincreaseduseRECENTFINDINGS:Countriesimplementingwitnesseddramaticcaseslargestdeclinefollowedintroduction7-valentdecreasesfollowingswitch13-valentPCV13gainsstilloccursmuchlowerratesLikewisepneumoniahospitalizationsofficevisitsotitismediadecreasedNasopharyngealcolonizationpneumococcipersistedduereplacementnonvaccineserotypes:colonizingnon-PCV13serotypeslessalsomarkedproportionsshowingnonsusceptibilityresistanceantimicrobialagentsFurthermoreexcellentprofileSUMMARY:provenefficacycountriesincluderesultingmajorityglobaldeathsattributableIncreasedworldwidehigherholdspromisePreventioninfectionschildhood:twodecades

Similar Articles

Cited By (3)